The potential role of HLA typing to risk stratify melanoma patients on immunotherapy with associated SJS: pitfalls and opportunities

Int J Dermatol. 2022 Sep;61(9):e335-e337. doi: 10.1111/ijd.15794. Epub 2021 Jul 24.

Authors

Elizabeth Schoenberg¹, Darius Mehregan², Beth Colombe³, Ezra Hazan⁴, Bahar Dasgeb⁵

Affiliations

¹ Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
² Department of Dermatology, Wayne State University, Detroit, MI, USA.
³ Histocompatibility and Tissue Typing Laboratory, Thomas Jefferson University, Philadelphia, PA, USA.
⁴ Private Practice, New York, NY, USA.
⁵ Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

PMID: 34302353
DOI: 10.1111/ijd.15794

No abstract available

Publication types

Letter

MeSH terms

Anticonvulsants / adverse effects
Genetic Predisposition to Disease
Genotype
HLA-B Antigens / genetics
Histocompatibility Testing
Humans
Immunotherapy / adverse effects
Melanoma* / complications
Melanoma* / therapy
Stevens-Johnson Syndrome* / complications

Substances

Anticonvulsants
HLA-B Antigens